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Anesthetics gain access to all parts of the body and thus interact 
at the molecular level with every component in the biosphere including lipids, 
proteins and even oligosaccharides. In order for any of these interactions to 
cause the various physiological changes are affected and cause a change in the 
function of the system. Thus, to approach the molecular mechanism of action of 
general anesthetics it is now necessary to understand both the extent of its 
binding, factors affecting and the forces governing its interaction with the carrier 
protein which transport them to their site of action. Thiopental and midazolam are 
clinically used general anesthetics, which are transported primarily by HSA, in 
the blood. Binding parameters and modulating factors are therefore of the 
interest for both pharmacokinetics and pharmacodynamics of the anesthetic. We, 
therefore, characterized thiopental-HSA and midazolam-HSA interaction in 
solution, the basic binding interaction, conformational dependent binding, micro 
metal ions effect, influence of H3O * ion, effect of ionic strength by using 
fluorescence and circular dichroism spectroscopy. Thiopental and midazolam 
binds exclusively to HSA according to a two class binding model, showing both 
saturable and non-saturable binding sites. Midazolam binds with two fold higher 
binding affinity than the thiopental though with decreased binding capacity. 
Thiopental and midazolam binding is strongly modified by the HSA concentration. 
Conformational dependant binding is observed in NoB transition, in analogy with 
close barbiturate methohexital in both the cases. Binding between HSA and the 
two anesthetic was found to be decreased with respect to temperature. 
Midazolam-HSA complex showing higher thermal stability than the thiopental 
one. However, the Metal ions, whicli were used in the present study Zinc, Ferric, 
Cupric, Nickel made the binding sites more susceptible for interaction of both the 
anesthetics with HSA. The electrostatic interaction forces, van der waals forces 
and hydrogen bonds are also contributing for the interaction accompanied with 
hydrophobic interactions. The electrostatic forces were more prominent in the 
midazolam binding as compared to thiopental. The enhanced binding of 
H 
thiopental and midazolam in the presence of Cu (II), ensures conformational 
changes in HSA secondary structure at varying extends, reflects perturbation of 
the other ligand binding sites on the albumin molecule and clears dynamic 
consequences that correlate with the character of binding in these model 
proteins. Preferential binding of the thiopental and midazolam, further leading to 
the stabilization of different conformational states may underlie anesthetic-
induced protein dysfunction, as well as provide an explanation for heterogeneity 
of action. 
^ 
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Serum Albumin 
Serum albumin is located in every tissue and bodily secretions. 
About 40% of the total albumin is found in the circulatory plasma (Peters, 1992) 
whereas remaining 60% is distributed about half in viscera and half in muscle 
and skin (Rabilloud et al., 1988). The albumin concentration in plasma of an 
average person is about 35-50 g/l, which declines slightly with age (Cooper & 
Gardner, 1989) and is lower in newborns (Cartlidge & Rutter, 1986), and as low 
as 20 g/l in premature infants (Reading et al., 1990). Albumin is produced by liver 
at a rate of 0.7 mg/g liver per hour (Peters, 1985) Approximately 4-55% of 
albumin is replaced by hepatic synthesis daily (Olufemi et al., 1990). The 
turnover is first order with an average half-life of 19 days (Waldmann, 1977). 
Functions of serum albumin 
Albumin performs many vital functions in the body while circulating 
in blood plasma. It is mainly responsible for the maintenance of blood pH and 
contributes 80% to the colloidal osmotic blood pressure. It is the chief reservoir 
and carrier for long chain fatty acids (Brodersen et al., 1991) and mono-acyl 
phospholipids (Robinson et al., 1989). It binds to polyunsaturated fatty acids 
(Anel et al., 1989) and influence the stability (Haeggstrom et a!., 1983), 
biosynthesis (Heinsohn et al., 1987) and conversion of prostaglandins (Dieter et 
al.. 1990). li is involved in the transport of thyroid hormones (Mendel et al., 1990) 
and tryptophan (Herve et al.. 1982) through reversible binding. It is also involved 
in the transport of pyridoxal phosphate (Fonda et al., 1991), cysteine and 
glutathione (Joshi et al., 1987) by forming a covalent linkage with these ligands. 
Albumin is responsible for the transport and storage of many therapeutic drugs in 
the blood stream (Linup, 1987). Albumin micropheres are useful carriers of 
therapeutic agents (Morimoto & fujimoto, 1985). 
Physico-chemical properties 
Physico-chemical properties of HSA are summarized in table 1 The 
molecular weight of albumins is less than that of the most other plasma proteins 
and ranges in between 66.000 and 67,000 (Loo et al., 1991). Under neutral 
conditions of pH, albumin has an axial ratio of approximately 2.66 based on the 
X-ray crystallography data, which is in agreement with the value of 3.0 obtained 
from studies of dielectric and birefringence relation times (Moser et al., 1966). 
The solvent accessible surface and molecular volume are 28,202A°^and 
88,249A°^,respectively (Richards, 1985). Hydrodynamically, HSA shows a 
sedimentation coefficient, S 20. w of 4.5 x 10"^ ^ S. diffusion coefficient, D20, w of 5.9 
X 10'^ cm^/sec (Wagner & Scheraga, 1956; Squire et., 1968) and partial specific 
volume of 0.733 cc/g (Hunter, 1966).The intrinsic viscosity of the protein has 
been measured as 0.041 cc/g (McMillan, 1974). At physiological pH, the 
calculated net charge per molecule is -17 (Peters, 1985). The specific absorption 
coefficient, E^"**" 1cm at 278nm has been found to be 6.67 (Pace et al., 1995) 
Amino acid composition 
HSA is a single chain protein containing 585 amino acid residues 
(Peters, 1992). The amino acid composition of HSA is given in table 1. The 
protein contains appreciable number of half cysteine residue and is rich in acidic 
amino acid residue i.e. aspartic acid and glutamic acid (Brown Shockley, 1982). It 
is fairly hydrophobic. HSA does not contain any carbohydrate or any other non-
protein moiety. It has low contents of isoleucine, methionine and glycine and 
contains only one tryptophan residues (Carter & Ho, 1994). 
There are 17 disulfide bridges in albumin and the whole molecule Is 
characterized by a unique arrangement of double loops that repeat as a series of 
Table: 1 
Physico-chemical properties of Human Serum Albumin 
Property Value Reference 
Molecular weight 
Sedimentation coefficient S20, w (S) 
Diffusion coefficient D20, w (dcm^/s) 
Partial specific volume, V20 (cm^/g) 
Intrinsic viscosity,[n] 
Fractional ratio, f/fo 
Overall dimensions, A 
Isoelectric point 
E^°'*1cmat278nm 
Mean residual rotation,[m']233 
a-helix, (%) 
P-structure, (%) 
66500 Peters (1992) 
4.5 X 10'^ ^ Squire et ai. (1968) 
5.9 X 10^ Wagner & Scheraga (1956) 
0.733 Hunter (1966) 
0.041 McMillan (1974) 
1.30 Creeth(1952) 
41.6 X 140.9 Wright & Thompson (1975) 
4.7 Longsworth & Jacobsen (1949) 
6.67 Pace etal (1995) 
8443 Moore & Foster (1968) 
68 Reed etal. (1975) 
17 Reed etal (1975) 
Table: 2 
Amino acid composition of Human serum albumin 
Amino acid Residue per mole 
Aspartic acid 40 
Asparagine 14 
Threonine 33 
Serine 28 
Glutamic acid 59 
Glutamine 20 
Proline 28 
Glycine 16 
Alanine 47 
Cystine/2 34 
Cysteine 01 
Saline 36 
Methionine 04 
Isoleucine 14 
Leucine 61 
Tyrosine 20 
Histidine 17 
Lysine 56 
Tryptophan 01 
Arginine 23 
Total 585 
Calculated net charge (pH 7) 217 
Calculated mol mass (Da) 66500 
triplets. They are arranged in a series of nine loop-link-loop structures centered 
on eight sequential Cys-Cys pairs. The conformations of the disulphide are 
primarily gauche-gauche (CPi -S1-S2-CP2) with torsion angles clustering around 
80 (He & Carter, 1992). The repetition of these loops in a triplet fashion of large-
small-large can group these loops into three homologous domains (I, II & III) 
comprising of residues 1-190, 191-382 and 383-583 in the primary sequence of 
albumin (Brown, 1977). The sequence homology between these domains is 18-
25% (Brown, 1977). The charge distribution of HSA at neutral pH for domains 1,1! 
and III are -11,-7 and +1 .respectively (Peters, 1996) 
X-ray structure 
The three dimensional structure of HSA has been determined by 
X-ray crystallography at a resolution of 3.2A (He & Carter, 1992). Each of the 
three homologous domain (I, II & III) of albumin is further divided into two 
subdomains 'A' and 'B' (Figurel). The subdomains are extensively crosslinked by 
disulfide bridges, which form the basis of the occurrence of 9 loops (3 in each 
sub domain) in albumin molecule. Albumin structure is predominantly o-helical 
(Jacobsen, 1972; Sjoholm & Ljungstedt, 1973; McLachlan & Walker, 1977). 
There are 10 principal helices in each domain, hl-h 6 for subdomains A' and h7 
- h10 for subdomain 'B'. Further, the six subdomains share a common helical 
motif, which corresponds to the amino acids encompassed with in the double 
disulfide loops 1, 3, 4, 6, 7 and 9 where in each motif is related by pseudo two 
fold axis (1:168° , 11:163° , 111:175° ) (Carter & Ho, 1994). Distinct differences 
between subdomain 'A' and B' also exist .The subdomain 'A' supplement the 
three helix bundle on the C-terminal side with an additional but smaller disulfide 
double loop (loops 2. 5 and 8) to form a small globin-like fold that is extensively 
cross-linked by four disulfide bridges. The subdomain 'B' supplements the helical 
motif on the N-temiinal side with a conformationally extended [polypeptide to 
create a folding topology that closely resembles a simple up-down helical bundle. 
Fig. 1: X-ray Structure of Human Serum Albumin 
Subdomain 'A' and 'B' assemble through hydrophobic helix packing interactions 
primarily involving h2, h3 andhS. Additionally, the subdomains are linked together 
by a presumed flexible extension of polypeptide encompassing residues Lys106-
Glu119, Glu292-Val315 and Glu492-Ala511 in the domains I, II and ill 
respectively. Domains l-ll and ll-lll in turn are connected through extensions of 
hlO (l)-h1 (II) and h10 (Il)-h1 (III), respectively, creating the \SNO longest helices 
(Carters Ho, 1994). 
Albumin - iigand interaction 
A variety of endogenous and exogenous ligands are known to bind 
serum albumin (Fehske et al., 1981;Kragh-Hansen, 1985;Curry et al.. 1998). 
Ligand binding properties of albumin has t>een extensively studied in order to get 
an understanding about the role of albumin as a vehicle for biologically important 
ligands as well as about its tertiary structure (Lindup.1987). A variety of 
substances differing in structure and chemical properties are known to bind 
albumin in a reversible manner and their association constants ranges from 10^ 
to 10^ M^ (Peters, 1985; 1992; Kragh-Hansen, 1990; Carter & Ho. 1994). 
Ligands can be viewed either endogenous or exogenous and may be cationic, 
neutral or anionic in nature. Some of the cationic ligands known to bind albumin 
are small inorganic ions such as Ca^^ (Fogh-Andersen, 1977), Cu^' (Lau et al,, 
1974), Ni^' (Callan & Sunderman, 1973), Cd^^ Zn^' (Goumakos et al., 1991; Bal 
et al., 1994; Zhou et.al, 1994), Hg^^ (Sarkar, 1983), Au^* (Shaw, 1979), A P ' 
(Trapp, 1983) etc. Among the endogenous substances, various organic anions 
such as long chain fatty acids (Brodersen and Ebbesen. 1983; Spector, 1986). 
bilirubin (Brodersen, 1979;Tayyab & Qasim, 1987; Mir et al., 1992) and amino 
acids like tryptophan (Sollene et al., 1981; Zhang et al.. 1993) are important from 
biological point of view. In addition of these ligands, a large number of drugs are 
also known to bind to albumin via a few high affinity binding sites and several 
sites of lower affinity, after their administration into blood stream. These include 
tetracycline (Khan et al., 1998) adriamycin (Trynda-Lemeiesz & Kozlowski, 
1996), indomethicin (Hultmark et al, 1975;Trivedi et al, 1999), ibuprofen (Whitlam 
et al., 1979), warfarin (Moreno et al., 1999), diazepam (Muller & Wollert, 1979), 
digitoxin (Fehske et al. 1981), carprofen (Rahman et al., 1993), salicylic acid 
(Tiara & Terada, 1985) and cephalosporins (Tawara et al., 1992), diclofenac 
(Chamouara et al., 1985) and various anti-cancer drugs including camphothecin, 
topotecan (Burke & Mi,1994) and cisplatin (Neault et al.,1998).In addition to 
endogenous ligands as well as various drugs ,many organic dyes and pH 
indicator substances also bind to albumin (Klotz & Avers, 1953). Binding of these 
ligands have been studied in greater detail at molecular level by various workers 
(Pedersen et al., 1977;Brodersen, 1978; Sjoholm & Stjerna, 1981; Bree et al., 
1993;Yong, 1993). These studies have been proved useful in understanding the 
functioning of the albumin in the transport of these ligands under various 
conditions, due to the large number of ligands, which bind to albumin, it is difficult 
to think of the same number of binding sites on albumin molecule, and therefore, 
the binding initially has been considered as a non-specific process. Over the past 
few years, this view has been changed and now it is believed that there are a 
small number of distinct binding sites. Based on their binding studies, Sjoholm et 
al. (1979) proposed three different classes of binding sites, characterized as 
warfarin, diazepam and digitoxin binding sites. Although the discrepancies exist 
about the exact number of discrete binding sites on albumin, the general 
consensus is for the two binding sites for small heterocyclic or aromatic 
carboxylic acids, two to three unique long chain fatty acid binding sites separated 
from the binding sites for small anionic compounds and two distinct metal binding 
sites making an overall six dominant binding areas on albumin molecule (Lindup, 
1987). From the three dimensional structure of albumin, specialized cavities in 
the sub-domain HA and MIA have been identified as sites for small heterocyclic 
and aromatic carboxylic acids (He and Carter, 1992). Lately, Peters (1996) 
suggested that there are two major specific drug binding sites on serum albumin. 
Site I to which the ligands such as bulky heterocyclic anions with the charge 
situated in a central position of the molecule binds, and site II where generally, 
carboxylic acids with an extended confonnation and negative charge binds 
effectively (He & Carter, 1992; Yamasaki et al., 1996). 
The overall distribution, metabolism and efficacy of many drugs 
can be altered on their affinity to serum albumin (Carters Ho, 1994). The percent 
binding of thiopental in human plasma has been extensively studied using 
ultrafiltration, equilibrium dialysis and spectrophotometric techniques 
(Christensen, 1980) however the reported data is quite variable, primarily due to 
the differences in the sensitivity and specificity of methods used to determine the 
extent of binding. Although, high resolution crystal structure have been revealed 
major binding sites on human serum albumin (Carter & He, 1992; Christensen, 
1980) but the exact location of the thiopental and midazolam are still obscure 
and, therefore the binding parameters need to be assessed. 
Anesthetic supplements 
Thiopental: A Barbiturate 
Thiopental, the flagship of the barbiturate anesthetic group, has been 
for more than 60 years a standard anesthetic induction agent to which all others 
are compared. 
Barbiturate Development 
In 1864 Von Baeyer synthesized the first barbiturate, barbituric 
acid. The first hypnotic barbiturate, diethylbarbituric acid, was synthesized by 
Fischer and Mering in 1903. A number of other hypnotic-sedative barbiturates 
were developed and tested, but all had too slow onset and too long duration of 
action. In 1932 Weese and Scarf synthesized the first rapid onset, short duration 
barbiturate, the methylated oxybarbiturate hexobarbital. Unfortunately, 
hexobarbital caused undesirable excitatory side effects. Thiopental was first 
administered by Waters (Wisconsin) and Lundy (Mayo Clinic) in 1934. Thiopental 
proved to be fast and brief acting and devoid of excitatory side effects. When 
hexobarbital and thiopental were used to anesthetize the wounded at Pearl 
Harbor in 1941, there were so many deaths that intravenous anesthesia with 
these agents was later described as "an ideal method of euthanasia." (Halford 
FJ, 1943) A responding anonymous editorial correctly suggested that the cause 
of death might be the method of administration rather than any inherent 
barbiturate toxicity. In 1950 Brodie et al demonstrated that barbiturate hypnotic-
sedative activity was temiinated not by metabolism, but by redistribution from 
central neural sites of action to other body tissues. It was later shown (Price, 
1960) that during prolonged infusions, redistribution becomes less effective 
because redistribution sites approach equilibrium. 
Basic Barbiturate Pharmacology 
Chemistry and Formulation 
Barbiturates are derivatives of barbituric acid (2,4,6-trioxyhexahydropyrimidine): 
HO—<'s V 
keto-enol automatisms , of barbituric acid, 
devoid of hypnotic activity 
Clinically important hypnotic-sedative barbiturates have substitutions at sites 1, 2 
and, especially, 5 of barbituric acid. 
Barbituric acid may be described as a "cyclic ureide of malonic acid:" 
HO—V N- ^/ 
'"''' > Orf'^ => 
urea + malonic acid -> barbituric acid 
Keto-enol tautomerization allows formation of water-soluble barbiturate salts: 
NoOH ^ HOH 
NoO-^^2 
>^—A 
,^v 
N-
Hypnotically active barbiturates 
9 9 
<H2cH:cH2 .Nj ^  yCH2CH:CH2 H(CH2)2CH3 ^^^t^ , XH 
' A CH3 '^  
HgH2,2, CH3 
secobarbital thiamylal 
N 
O: 
P 
-• yCH2CH3 
. N ; H ( C H 2 ) 2 C H 3 
O 
pentobarbital 
^r 
N-
yCH2CH3 
N : H ( C H 2 ) 2 C H 3 
thiopental 
CH3 / ^ 
. l ^ i — • > :H2CH:<:H2 
o^ 
N X:K:=.CCH2CH3 CH3 
methohexital 
Na salts + 6% by weight NaCOs + H2O or NS = 2.5% thiopental, 
2% thiamylal,1% methohexital. Buffering action of NaCOa P'us atmospheric CO2 
maintains pH at 10 to 11. In less alkaline solutions, these barbiturates may 
precipitate as the free acids; so do not reconstitute with NS or LR; and do not 
mix with acidic solutions of other drugs. Properly reconstituted, refrigerated 
solutions of thiobarbiturates are stable for 1 week, while similar solutions of 
methohexital are stable for 6 weeks. 
Structure-Activity Relationsliips 
Hypnotic activity (Fukai et. al, 2004) side chains at position 5 
(especially if one of them is branched) Potency and duration of action; length of 
side chain at position 5 (so, secobarbital and thiamylal are slightly more potent 
than pentobarbital and thiopental, respectively). More rapid onset and shorter 
duration of action: sulfur instead of oxygen atom at position 2 (so thiamylal and 
thiopental have more rapid onset and shorter duration of action than secobarbital 
and pentobarbital, respectively). Increased incidence of excitatory side effects: 
methylation at position 1 (methohexital). Increased potency, rate of onset and 
short action: increased lipophilicity. Stereoiso merism : Though their l-isomers 
are nearty twice as potent as their d-isomers. barbiturates are marketed as 
racemic mixtures. Methohexital has two asymmetric carbon atoms, so exists as 4 
stereoisomers (alpha, beta-d, l-methohexital). The beta isomers are associated 
with extensive motor activity, so methohexital is marketed as racemic alpha-d.l-
methohexital. Different activities among different stereoisomers (enantiomers or 
enantiomorphs) is consistent with a site of action at a chiral center of a receptor 
or enzyme. 
Pharmacokinetics 
An intravenous barbiturate bolus distributes first into a "central 
blood pool" chiefly perfusing relatively low-volume, high blood flow organs such 
as the brain ( Russo, 1998). Rapid in vitro elimination of thiopental doses from 
brain (Librizzi, 2005) Elimination clearance contributes almost nothing to 
temnination of induction effect. Drug effect is terminated in large part by uptake 
into lean tissues such as muscle. First-pass pulmonary uptake of thiopental is 
about 14%. 
Pharmacodynamics 
Pharmacodynamics may be most easily elucidated by studying a 
continuous noninvasive measure of drug effect. Thiopental is studied by Russo & 
Bressdie F., 1998. Effect of acute experimental lies dysfunction of the 
pharmacodynamics of hepatobarbital (Hoffman, 1993) Gender difference in the 
pharmacodynamics of barbiturate has been reported (Hoffman, 1989). 
Clinical Pharmacology and Uses 
Altered responses to induction doses of barbiturates are due altered 
pharmacodynamics or early distribution pharmacokinetics. The classic example 
is of hypovolemic shock. In this situation, the brain receives a higher fraction of 
the induction dose and removal is quite slow because of decreased blood flow to 
other organs. Thiopental induced changes in the contraction pattern of vascular 
smooth muscle (Andreasen. 1984). Effect of thiopental on the chemotaxis of 
eosinophils has been shown in vitro by Krumbolz (1999). Higher dose 
administration resulting in increased toxicity and complications has also been 
reviewed in thiopental therapy for head injury patients (Giraud, 1998) 
Mechanism of Action 
Most likely site of action: gamma-aminobutyric acid (GABA) receptor complex, 
GABAA. Effects on GABAA occur at clinical drug concentrations, correlate with 
anesthetic potency and are stereospecific. GABAA is the principal inhibitory 
neurotransmitter in the mammalian CNS. GABAA complex: oligomeric complex 
of 4 to 6 glycoprotein subunits assembled to form a ligand-gated chloride ion 
channel and activation (e.g. by GABA) leads to increased chloride conductance 
causing hyperpolarlzation, hence inhibition or decreased excitability, of the 
postsynaptic neuron (Olsen R.W., 1998) Barbiturates enhance and mimic the 
action of GABA at the GABAA receptor complex. BartDiturate binding to this 
receptor decreases the rate of GABA dissociation and increases the duration of 
GABA-activated chloride channel opening. A single amino acid confers 
bariDiturate sensitivity upon GABA rho 1 receptor (Lambert et al, 1999). 
Specific Organ Function Effects 
CNS effects 
Barbiturates may be hyperalgesic in subanesthetic doses. 
Thiopental produces dose-related depression of the EEG shown by delta and 
theta waves (increasing amplitude and decreasing frequency), burst suppression 
& flat line. 
intraocular pressure 
lOP decreases 40% after an induction dose of thiopental or 
methohexital. If succinylcholine is given immediately after thiopental, lOP returns 
to preinduction value. (Delay in giving succinylcholine leads to more elevated 
lOP.) 
Respiratory effects 
It causes Central respiratory depression. Both rate and depth of 
breathing are decreased. Respiration apparently returns toward normal in a few 
minutes, but responses to hypercarbia and hypoxia remain depressed for a 
longer time. Low incidence of hypersaiivation 
Cardiovascular effects 
These effects are predominant; venodilation leading to peripheral 
blood pooling Myocardial contractility is depressed to a lesser extent than with 
volatile agents(Sumitra M, 2004). Thiopental also dilates pulmonary vessels and 
decrease sympathetic output from the CN'S 
Midazolam: A Benzodiazepines 
Midazolam is a short-acting benzodiazepine central nervous system 
(CNS) depressant. 
Pharmacokinetics 
Midazolam is rapidly absorbed after oral administration and is 
subject to substantial intestinal and hepatic first-pass metabolism. It 
administration show withdrawal and dependency (Nelson, 1999). The 
pharmacokinetics of midazolam and its major metabolite, (alpha)-
hydroxymidazolam. and the absolute bioavailability of VERSED Syrup were 
studied in pediatric patients of different ages. They show more sensitivity for 
elderly (Greenblatt D.J, 1991) 
Pharmacodynamics 
Pharmacodynamic properties of midazolam and its metabolites, 
which are similar to those of other benzodiazepines, include sedative, anxiolytic, 
amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to 
result from reversible interactions with the (gamma)-amino butyric acid (GABA) 
benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the 
central nervous system. It leads to changes in hepatic metabolism on long time 
usage (Calarasu, 2004). In addition to its pharmacological action spectra, is 
known to exhibit varied effects like Neurotoxicity (Erdine, 1999) toxicity to mitotic 
cell division (Lafi, 1987) its role in brain death (Kuyotaka, 2003). Hypotension, 
bradycardia and tachycardia have been reported with overdose (Greenblatt et al., 
1977; Meredith & Vale 1985). 
Systematic description of clinical effects 
Cardiovascular 
Hypotension, bradycardia and tachycardia have been reported with 
overdose (Greenblatt et al., 1977;). Hypertension is more frequent when 
benzodiazepines are ingested in association with other drugs (Hojer et al, 1989) 
Respiratory 
Benzodiazepines may affect the control of ventilation during sleep 
and may worsen sleep apnoea or other sleep-related breathing disorders, 
especially in patients with chronic obstructive pulmonary disease or cardiac 
failure (Guilleminault, 1990). Respiratory depression requiring ventilary support Is 
been repoted in case of benzodiazepines (Sullivian, 1989). 
Pregnancy 
Passage of benzodiazepines across the placenta depends on the 
degree of protein binding in mother and fetus, which is influenced by factors such 
as stage of pregnancy and plasma concentrations of free fatty acids in mother 
and fetus (Lee et al., 1982). 
Breast feeding 
Benzodiazepines are excreted in breast milk in significant amounts 
and may result in lethargy and poor feeding in neonates. Benzodiazepines 
should be avoided in nursing mothers (Brodie, 1981; Reynolds, 1996). 
GABA and benzodiazepine binding to the GABAA receptor. 
This information was obtained from studies on cells coexpressing a1, P2 and Y2 
subunits; other subunits may not yield identical results. The additional subunits 
(with question marks) are shown for illustrative purposes only, as the 
stoichiometry of native GABAA receptors is still under investigation. (Smith and 
Olsen, 1995.) 

1.0 MATERIALS 
1.1 .proteins 
Human serum albumin (96-99% purity) purchased from Sigma 
chemical company, St.louis, MO63103, U.S.A Commercial preparation of HSA 
was made free from dimmers and other aggregated forms by passing through 
sephadex G-100 (2.5 x 100 cm) column. This preparation was used throughout 
these studies. 
1.2.Drugs/Ligands 
Thiopental sodium (sodium 5-ethyl-6 oxo-5-pentan-2yl-2-sulfanyl-
pyrimidin-4-olate) a barbiturate and Midazolam () a benzodiazepine were 
obtained from Ranbaxy, India. 
1.3.Reagents used in protein estimation 
Analytical grade samples of sodium potassium tartarate, sodium 
carbonate and copper sulphate were obtained from Qualigens. Folin-phenol 
reagent was prepared according to the standard procedure (Folin & Ciocalteu, 
1927). Copper reagent was prepared by mixing 1 volume of 4%(w/v) sodium 
potassium tartarate with 100 volumes of 4% (w/v) sodium carbonate and finally 
adding 1 volume of 2% (w/v) copper sulphate. 
1.4. Other reagents 
CuCl2, NiCl2, ZnCl2 and FeCb were obtained from Merk, India.Trizma-
base (Tris [hydroxymethyl] aminomethane) ultra pure procured from Germany. 
Disodium hydrogen phosphate, potassium dihydrogen phosphate, sodium 
chloride, sodium hydroxide, Ethylene diaminetetra acetic acid (EDTA), sulphuric 
acid and hydrochloric acid were procured from Qualigens Fine Chemicals, India. 
1.5.Miscellaneous 
Millipore filters (pore sizes 0.22 ancl0.45m) were purchased from 
Millipore Pvt. Ltd., Bangalore, India.Watman filters papers (No.1) were the 
product of Watman International Ltd., Maidstone, England.Parafilm 'M'was 
purchased from pechney plastic packing, Chicago IL60631. Aluminium foil was 
purchased from S.R.Foil Ltd.New Delhi, India. Double distilled water was used 
throughout these studies. 
2.0 METHODS 
2.1. pH measurements 
pH measurements were carried out on cyber scan digital pH meter 
model 510 attached with a thermal probe .The pH meter was routinely calibrated 
at room temperature with standard buffers. The pH was adjusted using 1N 
hydrochloric acid and 1N sodium hydroxide with constant stirring. 
2.2. Determination of protein concentration 
The protein concentration was determined either spectrophotometrlcally 
or by the method of Lowry et al. (1951). 
(a) Spectrophotometric method 
Protein concentration was determined following absorbance 
measurement at 278 nm on the shimadzu UV-Visible spectrophotometer, model 
1602.and using the value of specific extinction coefficient (E °^'^ 1cm) as for HSA 
(Paceetal, 1999) 
(b) Method of Lowry et aL (1951) 
Increasing volumes of the stock protein solution (SOOpg/ml) in the range 
of 0.1-1.0 ml were taken in the different test tubes and the volume in each tube 
was made to 1.0 ml with 10 mM sodium phosphate buffer, pH 7.0. Then, 5.0 ml 
of freshly prepared copper reagent was added to all the tubes and the contents 
were mixed well. After 10 min of incubation at room temperature, 1.0 ml diluted 
Folin-phenol reagent was added and vortexed. The tubes were incubated for 30 
min at room temperature and the colour intensity was read at 700 nm against a 
reagent blank. A calibration curve, was thus obtained, between absorbance at 
700 nm and amount of protein yielded the following straight line equation 
(Figure. 1) 
(Absorbance) 7oonm = 1.4 x 10-3 (protein concentration pg/ml) = 0.05 
3.0 Fluorescence spectroscopy 
These inhaled anesthetics contain heavy atoms that can quench 
aromatic amino acid fluorescence if bound in the immediate vicinity (<5A°) 
(Johansson & Eckenhoff, 1995). Hence, in order to determine whether the 
various injected anesthetics can gain access to and exhibit selectivity for the 
aromatic amino acid, especially tryptophan and phenylalanine, fluorescence 
quench titration was done according to the method of Levine (1977). 
3.1. Basic binding Interaction 
The titration was performed by adding aliquots of thiopental to a 
fixed concentration of protein albumin (2.0 pM) solution. Thus the molar ratio 
range (0-15) was obtained and the resultant decrease in protein fluorescence 
was measured at each moiar ratio. Further we increased the substrate (albumin) 
concentration to 4.0 and 6.0 pM in the different set of study and titrated it against 
thiopental (ligand) by adding constant molar ratio to evaluate the substrate 
dependant ligand binding. The relative fluorescence was determined for each 
spectrum and percent quench was calculated to study the interactions. 
3.2. Conformational Dependence Binding 
It has already been shown that human serum albumin exits in two 
conformational forms called N- and B- form (Wilting, 1979). This N <^ B transition 
in human serum albumin, occurring between pH 6 - 9. In phosphate buffer at pH 
6 almost all the protein Is in the N- forni and at pH 9 B- form is predominant 
(Takala & Soukka, 2004). Hence the binding studies were carried out for these 
two conformational states by titrating the fixed concentration of HSA in specific 
conformational state against equimolar thiopental as starting concentration. 
The study of binding was further extended with varied parameters like different 
ionic strengths, micro metal ions, temperature and hydronium (H+) ion 
concentrations. 
3.3. Fluorescence measurements 
Fluorescence measurements were made on a Shimadzu 
spectrofluorometer, (model RF-540) equipped with the data recorder DR-3. The 
fluorescence spectra were measured at a protein concentration of 2.0 pM (except 
the substrate dependence) with 1 cm path length cell. Excitation and emission 
slits were set at 3 and 4 nm respectively. The spectra were recorded in 300-400 
nm range and the excitation wavelength was set at 280nm. All the stock solutions 
were filtered through 0.20 pm Millipore filters prior to mixing, to minimize the 
inner filter effect (Chignell, 1972). 
3.4. Binding analysis 
The fluorescence intensity values at emission maximum (340nm) 
were used for calculating the relative fluorescence, considering the fluorescence 
intensity of untreated control as 100. The least square analysis of the initial linea 
points of relative fluorescence versus drug to albumin molar ratio was used to 
determine the maximal quench, m (slope of the plot) from the following equation 
(F=Fo-m R); where, F is the fluorescence intensity and R drug to albumin molar 
ratio and Fo is fluorescence intensity of protein at zero drug concentration. Using 
the data points exhibiting deviation from the straight-line behavior, the fractional 
quench, Q, was detemriined at each drug/albumin molar ratio (R). This is 
obtained from the equation (Q=Fo-F/m). Fractional quench, Q is linearly related to 
drug binding: (Drug Albumin)/(Albumin)T=Q, where, the (Albumin) T represent the 
total albumin concentration. Binding affinity (Ka) and Binding capacity (n) were 
determined from the slope and intercept on X-axis of the straight line on the 
scatchard plot Q vs. Q/(R-Q) (Albumin) T (Levine, 1977). 
4. Circular dichroism measurements 
CD spectra of thiopental-albumin complex in the presence of Cu (II) 
ions were measured on the Jasco-810 spectropolarimeter, coupled to a 
microcomputer for data analysis. The instrument is routinely calibrated with D-10-
camphorsulphonic acid. All the CD measurements were performed using 1 cm 
path length quartz cell at 25° C with thermostatically controlled cell holder 
attached to a NESU\B RTE-110 circulating water bath (NESLAB instruments, 
Inc., USA) with an accuracy of ± 0.1° C. All the spectra were collected at a scan 
speed of 50 nm min ~\ data interval 0.2 with a response time of 1 sec. Each 
sample was scanned three times and high frequency noise reduction was 
applied. Each spectrum was corrected by subtraction of a buffer as blank under 
identical conditions. The results expressed as molar ellipticity (6)^ in the degree 
cm^ dmor\ which is defined as: 
(e)x= lO0/cd 
Where 0 is the observed ellipticity in degrees, c is the concentration in mol I "' of 
total drug and d is the path length in decimeter. 
The Jasco spectropolarimeter is equipped with a software based 
on Yang equation (Chen & Yang, 1971) to calculate the secondary structure 
which gives the extent of the a helix and p sheets and random coil in a protein. 

1.0 INTRODUCTION 
Thiopental, an intravenous anesthetic is a barbiturate (Figl), used 
frequently by anesthesiologist prior to surgery and other invasive medical 
procedures, in psychotherapy and some medical conditions like hypoxia and 
ischemia (Basagon, 2005). In addition to its pharmacological action spectra, 
thiopental is known to exhibit varied effects like increase in pulmonary 
inflammation (Skarlosh, 1974), which worsen the inflammatory injury and 
disease. Also due to its slow elimination rate results In minor CNS depression, 
thiopental affects the biligenic functions of liver and also reported to cause 
drowsiness in the newborn baby as the drug pass into breast milk (Schalen, 
1992). It has been accessed that thiopental show variation in its response form 
indivisual to indivisual (Christensen, 1978). Thiopental induced changes in the 
contraction pattern of vascular smooth muscle (Andreasen, 1984). Effect of 
thiopental on the chemotaxis of eosinophils has been shown in vitro by Krumbolz 
(1999). Higher dose administration resulting in increased toxicity and 
complications has also been reviewed in thiopental therapy for head injury 
patients (Giraud, 1998) and other severe patho-physiological hazards of other 
anesthetics (Quedraogo, 1998; Rich. 1994; Nyhan, 1989). Cardiac disrhythmias 
associated with intravenous delivery (Roelofse, 1994) associated with sudden 
cardiac death has been reported with thiopental anesthesized subject (Kessler, 
1995). This instills in us the vitality to investigate its entrepreneur interactions 
with HSA, which represents important and most abundant constituent of blood 
plasma and serving as a depot protein. Indeed, a better understanding of the 
important binding parameters influencing the transport, metabolism, elimination, 
bioavailibility and toxicity of these drugs in the body is needed. 
It is important to quote that saturable binding of some anesthetics 
to HSA induce alterations in the structure and function of this protein. (Eckenhoff, 
1993; Johansson, 1995; 1997; Tanner, 1999). However, competitive binding 
displayed by different ligands may result from allosteric effects, whereby binding 
of ligand A at a certain site causes a conformational change in the protein so that 
binding of ligand B at a different site Is altered (Miles et al,1962). The 
characteristic property of fluorescence of aromatic amino acids has been 
exploited to investigate a variety of binding interactions (Rajeswari M.R, 1992, 
1987; Jain Akiank, 2005). Hence Interaction of such ligands with HSA may lead 
to a significant change in the pharmacokinetics and transport of ligand molecules 
(Mostafa, 2002; Takala et. al, 2004). 
Hence, in view of the present background we initiated our study to answer 
various unsolved problems like, what precisely would be the affinity of binding 
and so the interaction of thiopental with HSA. Further more, we extended our 
study to find the effects of micro metal ions on the binding forces since they are 
the constituents of blood plasma. Among the various binding forces involved in 
the interaction, the electrostatic interactions were recently investigated as 
potential binding forces between anesthetic and HSA (Tang, 2000). And hence, 
we investigated the effects of ionic concentration on binding as well as the effect 
of protein charge distribution due to changes in H* ion concentration. We have 
also evaluated the binding strength and capacity of thiopental to bind with two 
conformational forms of serum albumin the so-called N and B forms at pH 6 and 
9 respectively (Leonard, 1963; Wallevik, 1973; Saroff, 1963; Nickel, 1971). The 
understanding of the binding interactions of thiopental with HSA will also allow 
refinement of pharmacokinetic models. These studies were carried out by using 
sensitive technique such as fluorescence spectroscopy and circular dischroism. 
2.0 METHODOLOGY 
We, performed the thiopental-HSA interaction study in solution 
and evaluate the basic binding interaction, conformational dependent binding, 
micro metal ions effect, thermal stability, influence of H ^ ion, effect of ionic 
strength by using fluorescence spectroscopy. The titration was performed by 
adding aliquots of thiopental to a fixed concentration of protein albumin (2.0 pM) 
solution. Thus the molar ratio range (0-15). The protein was excited at 280 nm 
and the emission at 340 nm was treated as maximum and used for the 
interpretation of the results. Also the change in the tertiary structure of Human 
Serum Albumin due to the binding was followed by circular dichroism. CD 
spectra of thiopental-albumin complex in the presence of Cu (II) ions were 
measured on the Jasco-810 spectropolarimeter, coupled to a microcomputer for 
data analysis. All the spectra were collected at a scan speed of 50 nm min ~ , 
data interval 0.2 with a response time of 1 sec. Each sample was scanned three 
times and high frequency noise reduction was applied. 
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Fig .1 . Chemical structure of thiopental sodium, a barbiturate anesthetic. 
3.0 RESULTS 
3.1. Basic Binding Interaction 
The interaction of thiopental with Human serum albumin were analyzed by 
monitoring the changes in the intrinsic fluorescence of protein at different 
drug/albumin molar ratios. Fig.2 (a) shows the representative fluorescence 
emission spectra with maximum at 340 nm upon excitation at 280 nm. Adding of 
thiopental in ascending concentration to fixed amount of protein progressively 
decreased its fluorescence intensity. The inset of Fig.2 (b) illustrates binding 
isotherms; which shows drug concentration dependent quenching of HSA. In the 
scatchard plot analysis, the slope provided the association constant ka=7.5 x 10^ 
I mol"^  and intercept on X-axis measured binding capacity, n=12.9 Fig.2 (b) which 
demonstrated high affinity binding with large number of binding sites. 
3.2. Substrate Dependent Binding 
It has been observed that the binding parameters increased with the 
increasing concentration of HSA (substrate) at fixed thiopental (ligand) molar 
ratios as shown in Fig.3 (a). It was also observed that the quenching effect was 
increased at ascending concentration of albumin, confirming the increased in 
forces and parameters governing this particular binding interaction (Fig.3 b). 
3.3. Conformational dependence binding 
The N to B transition of serum albumin led to the change in its 
conformational state. It displayed the difference in its thiopental binding pattern. 
Fig.4 (a). Fig. 4 (b) showed that the quenching was more pronounced in B-form 
compare to N-form. Furthermore, scatchard plot analysis (Flg.4 a, b inset) 
calculated the binding constant KN=0.75 X 10"* and KB= 2.4 X lO'' with the binding 
capacity n= 13 and 10 respectively. Which suggested the greater number of 
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Fig.2(a). Fluorescence emission spectra of HSA (2MM) in Tris-HCI buffer, pH 7, 
temp.25°C in the absence and presence of increasing amount of 
thiopental after exciting it at 280nm with molar ratio of drug to HAS 
ranging fromO.O to 17. 
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quenching titration data was fitted with equation shown as inset for 
the binding of thiopental with albumin. 
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Fig.4. (a) Binding isotherm showing the thiopental induced quenching of HSA 
fluorescence at N- conformational state with an inset showing the 
scatchard plot for binding parameters. The experimental conditions 
are phosphate buffer pH 6 and at 25°C. 
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Fig.4. (b) Binding isotherm showing the thiopental induced quenching of HSA 
fluorescence at B- conformational state with an inset showing the 
scatchard plot for binding parameters. The experimental conditions 
are phosphate buffer pH 9 and at 25°C. 
binding sites with lower affinity in the N-form and less number of binding sites 
with higher affinity in the B-form (three fold increase). 
3.4. Effect of Temperature on Binding 
A trennendous increase in the binding was observed at low temperature 
for B-conformation while N-confomiation showed least binding. The fact that, 
curve showing reduction in fluorescence intensity at fixed thiopental 
concentration vs. variable temperature (Fig.5) was displaced from parallel to a 
higher level at low temperature indicated that more thiopental was bound at low 
temperature (Fig.5). Furthermore, at higher temperature the deviation of curve 
from parallel behavior showed the conformational dependent loss of binding 
Moreover, thermal stability of both conformations was found to be comparable at 
higher temperature as shown in fig.5. 
3.5. Effect of Micro Metal Ions on Binding 
It has also been demonstrated earlier that metal ions bind with protein. 
Moreover, the presence of metal ions directly affects the interaction between the 
drug and the protein (Wilting, 1979; Quagraine, 2001; Zhang, 1999). We studied 
four metal ions Cu^*, Fe^*, Ni^*& Zn^* because the traces of these are present in 
blood plasma. Protein concentration of 2.0|JM was treated with metal ion and the 
effect was evaluated on the binding reaction by calculating the percent quench in 
its presence. The percent fluorescence was found to be decreased with the 
different treatment of micro metal ions Fig.6 (a). Among the four metal ions 
studied, the pronounce effect on binding was shown by copper Fig.6 (b). The 
highest percent quench was observed for copper than iron, nickel and zinc in 
descending order (Table 1). 
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Flg.6 (b). Effect of Cu (II) on HSA fluorescence. HSA fluorescence was 
measured in absence and presence of 10 pM thiopental and 10 pM 
Cu (II). The spectra represents (a) HSA alone (b) HSA +Cu (II) (C) 
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Table .3. Effect of certain metal ions on thiopental -USA binding 
Metals 
Control 
Cu'^ 
Zn-^ 
ithout Drug 
0.0 
28.0 
12.6 
8.9 
3.0 
Percent Quen 
With Drug 
13.0 
42.2 
17.3 
16.7 
15.0 
3.6. Effect of Ionic strength 
Studies in the past three decades have concluded that an 
anesthetic binds to hydrophobic regions within the protein through van der waals 
interactions and the hydrophobic effect. (Ekenhoff, 1997; Franks, 1994; 
Hameroffs, 1998). Since it has been shown earlier that electrostatic interactions 
are major binding forces between anesthetic and protein (Franks, 1998). Hence, 
we investigated the effect of ionic environment on binding affinity. Study was 
made on increasing ionic concentration of NaCI (100, 300, and 500 mM) 
Our results indicated that with the increase in the ionic strength, the affinity 
of HSA for thiopental increased from 100 to 300 mM NaCI concentration. Further 
increase to 500 mM NaCI concentration led to the decrease in the binding 
affinity, generated more number of binding sites The quenching trend in all three 
concentrations illustrated that at higher concentration of drug the electrostatic 
forces are more dominant than at low molar ratios Fig.7 (a). A maximum percent 
quench was found at 500 mM NaCI concentration that is 28%. The binding 
constant (Kg) exhibited a linear relation ship at 100 and 300 mM NaCI (Na^ ions) 
then fell down, when log Kg was plotted as a function of -log (Na') as shown In 
Fig. 7 (b). 
3.7. Hydronlum (H*) ions and binding parameters 
It Is well known fact that compartmentalization of human coelomic 
cavity which generates in different compartments with varying hydronlum ions 
concentrations and lead to varying charge distribution on protein. Hence to 
assess the effect of hydronlum ions we have taken three basic concentrations 10 
^ 10^ and 10"^  for evaluation of capacity and extend of binding. 
We have also investigated binding parameter at different hydronlum ion 
concentration. Fig.8 (a) showed the relative fluorescence on titration of thiopental 
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Fig.7 (a). Fluorescence quenching trend of HSA at different NaCI concentrations 
at fixed drug /HSA molar ratio, with HSA concentration (2|JM). All other 
experimental conditions are same as given in fig.2. 
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Fig8 (b). Scatchard plot analysis of thiopental HSA binding in the presence of 
different HaO" ions concentration (i) 10"^ (ii) 10''' (iii) 10"^ M. 
at three (H*) concentrations that are 10'^ , 10'^  and 10'^  M. The result illustrated 
the maximum quenching effect in the presence of 10"^  M H* ions The reduction 
in the fluorescence was progressive at 10"' and 10"'' but at 10"^  M initially the 
quench was concentration dependant and comparable to 10"^ M H^ but later it 
showed saturating trend. The association and binding constants (Kg and n 
respectively) were calculated for all three concentrations of H"^  ions by scatchard 
plot (Fig.8 b, c, d) and the values obtained were Ka= 0.025 x 10^, 0.007 x 10^ and 
0.020 X 10^ n = 7. 12.9 and 9.7 for 10"^ 10'^ and 10"^  M H* ions respectively. 
3.8. Conformational changes followed by CD spectroscopy 
The changes in the secondary structure of HSA induced by thiopental 
and its copper complex were also analyzed by circular dischroism spectra. The 
CD spectrum of native HSA alone showed very neat peaks at 208 and 222 nm, 
which are negative. The addition of thiopental alone did not change the spectral 
pattern and the secondary structure (see curve b, Fig 9). However the addition of 
copper with thiopental has drastically changed the ellipticity (70%) as seen in Fig 
9 (curve c), which further increases on addition of the thiopental from (0.2mM to 
1 .OmM). The change in ellipticity is accompanied by the decrease in a helix by 
12% without affecting the p sheet structure illustrating the destabilization of the 
secondary structure of HSA. 
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Fig.9. The spectra of HSA of native, (a); native+0.2mM thiopental, (b); 
natlve+0.2 mM thiopental+0.2mM Cu (II), (c); native+0.4mM 
thiopental+0.2mM Cu (II), (d); native+O.SmM thiopental+0.2mM Cu (II), 
(e); native+1.0mM thiopental+0.2mM Cu (II), (f) respectively. 
4.0 DISCUSSION 
This is the first report that shows a potential binding of thiopental with a 
high affinity and binding capacity for Human serum albumin with various 
parameters. The binding parameters under the influence of modulating factors 
such as substrate dependant binding, confomiational state, ionic strength, 
hydronium ion concentration, temperature relation with binding and metal ions 
effect were not been studied earlier. Our study contributes significant information 
from both clinical and pharmacological point of view. 
4.1. Number of binding sites and affinity 
We investigate the two types of biding sites for thiopental on HSA. Our 
data, on the decrease in linearity of the quenching pattern of concentration 
dependent binding suggest the presence of the two different binding sites on 
HSA for the drug. Moreover, this data also suggest that high affinity binding sites 
show a linear quenching pattern where as low affinity binding sites exhibit 
unsaturable pattern of binding. This finding is consistent with the previous studies 
carried out by equilibrium dialysis technique (Chhstensen & Andreasen, 1980), 
which is not as sensitive as the present study. The plot constructed from the 
experiment with constant thiopental concentration and increasing albumin 
concentration shows increase in the magnitude of Kg and n, the binding 
parameters. Such substrate dependent binding has also been reported by Shen 
& Gilbaldi (1974). This could be explained by the fact that each albumin molecule 
represents a large lipophilic or at least hydrophobic area for lipophilic thiopental, 
which provides better site for localization of thiopental molecule and so it makes 
our study in favors of the binding experiment of thiopental as were carried out 
previously with higher protein concentration using ultrafilteration and equilibrium 
dialysis (Christensen, 1980). 
4.2. Modulating factors and binding 
The result of binding in different conformational states shows high binding 
affinity for the B-conformational state of protein as compared to N- state. The 
reason for this discrimination in binding is flexible nature of B-form as compare to 
compact N-forni. This is why probably; B-form of protein provides better 
localization of drug and so increases its binding affinity. Another significant 
reason for the strong binding with B-form might be the close proximity of drug 
molecule to the domain III (Dockal, 2000), which is further contributing to 
increase in high affinity binding sites. The increase in binding affinity with the 
decrease in binding capacity suggests the decrease in binding sites of low affinity 
and increase in high affinity binding sites due to conformational change. The 
decrease in binding sites from N- to B- form has also been described previously 
for warfarin (Wilting, 1980). Our results are also consistent with the number of 
reports dealing with conformation dependence binding (Rosen, 1970; Janssen & 
Nelen, 1979). 
We also observed that the variation in the temperature brings a significant 
change in the conformational dependant binding. The curve in figure 6 shows 
fluorescence reduction with a constant drug concentration, resulting decrease in 
binding. At low temperature more thiopental is bound. In fact the amount of B-
form of albumin is reduced from 0.67 to 0.11 (fraction) on reducing the 
temperature (Jcabsen & Faerch, 1980). This is because of the fact that the 
binding forces are reduced with the increase in temperature. But no evidence 
proves that lowering in temperature results in unfolding of the HSA and hence 
provides better accessibility for drug molecules to a new binding site. Our data 
that thiopental binding is increased with the decrease in temperature strongly 
supported by the finding of an increased olive oil/phosphate coefficient at low 
temperature (Christensen, 1983). A significant change in the B-form has been 
observed as compared to N-form, which is again, probably due to conformation 
dependent compact structure of N-form. 
The results about the enhancement of binding interactions in the presence 
of micro metal divalent ions are comparable to the earlier finding on the metal ion 
complexation with albumin (Kragh-Hansen, 1994) suggesting the potential of 
these metal ions present in our body influencing the binding reaction. Indeed, the 
residues at the N- terminus particularly histidine moiety at position 3, cys-34 and 
tryptophan are known to play a critical role in metal binding (Peters, 1967). Our 
results suggest higher binding in the presence of Cu (II) and least with 2n (II). 
This increase in the binding may be due to the formation of metal bridge, which 
provides better fit for drug molecule. This phenomenon imply that the binding 
force between the protein and the drug has been enhanced in the presence of 
metal ions, and so affects the pharmacokinetics of the drug in the blood plasma. 
4.3. Specificity 
The unsaturable fluorescence quench from binding spectra suggests the 
binding of thiopental molecule at a site possessing number of aromatic moieties. 
Further quenching effect at excitation wavelength for tryptophan (295nm) was 
negligible as compared to quenching at excitation wavelength for phenylalanine 
(280nm); depicts the presence of phenylalanine at the drug binding site. Through 
browsing the different domain structure of HSA, we found such a site present in 
domain III of the protein. As sub-domain IIIB lined by aromatic residues (Phe-
502, Phe-507, Phe-509, Phe-551) emitting fluorescence, which is also advocated 
further with our conformational dependant binding, showing more binding in B-
form which results in further opening of domain III by breaking the salt bridges 
(Dockal & Carter, 2000). The crystallographic data of subdomain IIIA had 
previously suggested it as one of the most important binding site termed site II by 
Sudlow et.al (1976) and can also accommodate diazepam, propofol and other 
aromatic anesthetics. Which further affinn the binding of thiopental at domain III. 
The two class of binding model is also justified by these sites, as the subdomain 
IMA is shown to be a site with weaker binding affinity as compared to site IIIB 
(Curry, 1999). This elucidates the presence of binding sites for thiopental in 
domain III. 
4.4. Binding forces 
Electrostatic interactions 
Increase in the ionic strength should screen charges in water accessible 
sites and reduce their effect on the ligand binding in the competitive way. Thus if 
electrostatic interactions were important, an increase in the ionic strength should 
reduce their contribution to binding and thus weaken binding due to screening 
effect of ions in these interactions (Liu, 2002). Hence, increase in the ionic 
strength from 100-300 mM strengthen association constant suggesting primarily 
other forces involved in the binding, but further increase in NaCI concentration 
decreases binding affinity which illustrates the role of electrostatic forces. The 
quenching trend with different ionic strength shows the effect of ionic strength at 
higher concentration of drug. Which illustrates the interference of ions due to 
their presence in the water accessible binding sites. The maximum quenching 
occurs at 500 mM NaCI concentration irrespective of the maximum binding 
affinity at lower ionic strength, this could be explained that with the increasing 
ions concentration binding capacity increases and leading to more binding at 
higher ions concentration. This suggests that with increase in ions there is a 
change in protein conformation, which may lead to unfolding of the structure. 
The change in H* ions concentration leads to a difference in charge 
distribution on the protein due to different degree of ionization, depending on 
different pKa value of constituent amino acids. The protein is more ionized at two 
extreme of H* concentrations (10~^ to 10~^  M), which in turn generates a strong 
electrostatic force, and hence leads to high binding affinity compare to lO'^M. 
This kind of binding makes it slow eliminating even at high H'^ ions concentration. 
The 7t electrons of the thiopental aromatic ring contribute partial negative 
charges that can interact with cations and other partial positive charges 
(Dougherty, 1996), which further advocate the electrostatic forces. 
Hydrophobic interactions 
The lipophilic nature of the thiopental predicts the role of hydrophobic 
forces in the interacton. Guided by the Meyer-Overton correlation between 
anesthetic potency and solubility in a lipid like environment, had suggested that 
anesthetics must bind to hydrophobic regions (Franks & Lieb, 1994). Our result 
with ionic strength has shown insignificant electrostatic forces at lower salt 
concentration in water assessable sites. As the drug binds to buried hydrophobic 
sites which are undisturbed by ionic strength approachable to water assessable 
region of the domains, leaving hydrophobic interactions as the dominant feature 
of thiopental-HSA interaction. 
Van der Waats interactions 
In view of the structure of thiopental, which lack formal charges and have 
small dipole moments, van der waals forces must play an important role in the 
stabilizing energetics that govern their binding to a protein (Zhang & Yang, 1999). 
Van der waals forces are derived from short-range, transient electrostatic 
interactions, and can be predicted to be larger for thiopental, since its larger 
surface contact as depicted in the scatchard analysis. Therefore, in addition to 
electrostatic interactions, van der waals forces must also contribute to the more 
capacity and the higher affinity of the thiopental-HSA complex. 
Hydrogen bonds 
Thiopental may act as both a hydrogen bond acceptor and donor, due to 
the presence of both electropositive and electronegative functional groups 
attached to its aromatic ring (Fig 1). In the earlier studies it was found that the 
aromatic ring lies within an apolar pocket with the phenolic hydroxy group in 
close proximity for establishing a hydrogen bond, with main chain moieties of 
Leu*^ ° residue and Ser^ ™ in domain IHA and IIIB respectively (Bhattacharya, 
2000). This is similar as per our elucidation for specificity of binding sites of 
thiopental. 
4.5. Protein secondary structure 
The excessive binding of thiopental to HSA-Cu (II) complex led changes in 
the microenvironment, which in tum destabilize the carrier protein. CD data also 
show no change in ellipticity in the absence of Cu (II) ions, which suggests that 
the copper ions enhanced the binding of thiopental to serum albumin. This is 
probably due to the formation of the metal ion bridges which provide the 
appropriate binding sites for the drug interactions (Peters & Jr. Blumenstock, 
1967). This observation corroborates the fluorescent data, exhibiting significant 
quenching of protein fluorescence (42.2 %) in the presence of thiopental and Cu 
(II) ions compared to 13% with thiopental alone. 

1.0 INTRODUCTION 
Midazolam an intravenous class IV anesthetics a 
benzdiazepines; with imidazole structure, used frequently by anesthesiologist 
prior to surgery and other invasive medical procedures as a sedative and also as 
an anxiolytic, amnesia and hypnotic. This medication onset sedation quicker and 
of short duration. In addition to its pharmacological action spectra, is known to 
exhibit varied effects like Neurotoxicity (Erdine, 1999) toxicity to mitotic cell 
division (Lafi, 1987) its role in brain death (Kuyotaka, 2003). Hypotension, 
bradycardia and tachycardia have been reported with overdose (Greenblatt et al., 
1977; Meredith & Vale 1985). Benzodiazepines may affect the control of 
ventilation during sleep and may worsen sleep apnoea or other sleep-related 
breathing disorders, especially in patients with chronic obstructive pulmonary 
disease or cardiac failure (Guilleminault, 1990). Benzodiazepines have been 
reported to affect endocrine system as Galactorrhoea with normal serum 
prolactin concentrations has been noted in 4 women taking benzodiazepines 
(Kleinberg et al., 1977). Gynaecomastia has been reported in men taking high 
doses of diazepam (Moerck & Majelung, 1979). Hypersensitivity reactions 
including anaphylaxis are very rare (Brigby, 1986). Passage of benzodiazepines 
across the placenta depends on the degree of protein binding in mother and 
fetus, which is influenced by factors such as stage of pregnancy and plasma 
concentrations of free fatty acids in mother and fetus (Lee et al., 1982). 
Benzodiazepines are excreted in breast milk in significant amounts and may 
result in lethargy and poor feeding in neonates (Brodie, 1981; Reynolds, 1996). 
This instills in us the vitality to investigate its entrepreneur interactions with HSA, 
which represents important and most abundant constituent of blood plasma and 
serving as a depot protein. Indeed, a better understanding of the important 
binding parameters influencing the transport, metabolism, elimination, 
bioavailibility and toxicity of these drugs in the body is needed. 
It is important to quote that saturable binding of some anesthetics to HSA induce 
alterations in the structure and function of this protein. (Eckenhoff, 1993; 
Johansson, 1995; 1997; Tanner, 1999). However, competitive binding displayed 
by different ligands may result from allosteric effects, whereby binding of ligand A 
at a certain site causes a conformational change in the protein so that binding of 
ligand'B at a different site is altered (Miles et al, 1962). The characteristic 
property of fluorescence of aromatic amino acids has been exploited to 
investigate a variety of binding interactions (Rajeswari M.R, 1992, 1987; Jain 
Akiank, 2005). Hence Interaction of such ligands with HSA may lead to a 
significant change in the pharmacokinetics and transport of ligand molecules 
(Mostafa, 2002; Takala et. al, 2004). 
Hence, in view of the present background we initiated our study to 
answer various unsolved problems like, what precisely would be the affinity of 
binding and so the interaction of thiopental with HSA. Further more, we extended 
our study to find the effects of micro metal ions on the binding forces since they 
are the constituents of blood plasma. Among the various binding forces involved 
in the interaction, the electrostatic interactions were recently investigated as 
potential binding forces between anesthetic and HSA (Tang, 2000). And hence, 
we investigated the effects of ionic concentration on binding as well as the effect 
of protein charge distribution due to changes in H* ion concentration. We have 
also evaluated the binding strength and capacity of thiopental to bind with two 
conformational forms of serum albumin the so-called N and B forms at pH 6 and 
9 respectively (Leonard, 1963; Wallevik, 1973; Saroff, 1963; Nickel, 1971). The 
understanding of the binding interactions of thiopental with HSA will also allow 
refinement of pharmacokinetic models. These studies were carried out by using 
sensitive technique such as fluorescence spectroscopy and circular dischroism. 
2.0 METHODOLOGY 
We, performed the midazolam-HSA interaction study in solution and 
evaluate the basic binding interaction, conformational dependent binding, micro 
metal ions effect, thermal stability, influence of H * ion, effect of ionic strength by 
using fluorescence spectroscopy. The titration was performed by adding aliquots 
of thiopental to a fixed concentration of protein albumin (2.0 pM) solution. Thus 
the molar ratio range (0-15). The protein was excited at 280 nm and the emission 
at 340 nm was treated as maximum and used for the interpretation of the results. 
Also the change in the tertiary structure of Human Serum Albumin due to the 
binding was followed by circular dichroism. CD spectra of midazolam-albumin 
complex in the presence of Cu (II) ions were measured on the Jasco-810 
spectropolarimeter, coupled to a microcomputer for data analysis. All the spectra 
were collected at a scan speed of 50 nm min ~\ data interval 0.2 with a response 
time of 1 sec. Each sample was scanned three times and high frequency noise 
reduction was applied. 
Fig.1. Chemical structure of midazolam a barbiturate 
3.0 RESULTS 
3.1. Basic binding interaction 
The interaction of thiopental with Human serum albumin were analyzed by 
monitoring the changes in the intrinsic fluorescence of protein at different 
drug/albumin molar ratios. Fig.2(a) shows the representative fluorescence 
emission spectra with maximum at 340 nm upon excitation at 280 nm. Adding of 
midazolam in ascending concentration to fixed amount of protein progressively 
decreased its fluorescence intensity. The inset of Fig.2(b) illustrates binding 
isotherms; which shows drug concentration dependent quenching of HSA. In the 
scatchard plot analysis, the slope provided the association constant ka=1.5 x 10" 
I mol^ and intercept on X-axis measured binding capacity, n=10.7 Fig.2b which 
demonstrates high affinity binding with large number of binding sites. 
3.2. Substrate dependent binding 
It has been observed that the binding parameters increased with the 
increasing concentration of HSA (substrate) at fixed midazolam (ligand) molar 
ratios as shown in Fig.3(a). It was also observed that the quenching effect was 
increased at ascending concentration of albumin, confinning the increased in 
forces and parameters governing this particular binding interaction (Fig.Sb). 
3.3. Conformational dependence binding 
The N to B transition of serum albumin led to the change in its 
conformational state. It displayed the difference in its thiopental binding pattern. 
Fig 4a Fig, 4b showed that the quenching was more pronounced in B-form 
compare to N-form. Furthemiore. scatchard plot analysis (Fig.4 a&b inset) 
calculated the binding constant KN=0.15 X 10^ and KB= 0.35 X 10^ with the 
binding capacity n= 10.7 and 9.7 respectively. Which suggested the greater 
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Fig.2 (a). Fluorescence emission spectra of HSA (2MM) in Tris-HCI buffer, pH 7, 
temp.25°G in the absence and presence of increasing amount of 
midazolam after exciting it at 280nm with molar ratio of drug to HAS 
ranging from 0.0 to 17. 
2.4 
2.3 
•p 2.2 -I 
E 
O 
I 
O 2.0-
1.9 
18 
(Bng/tBnmnBi^malMriitki* 
m = 1.53x10 
(^ = 0.97 
11 
[Q] 
Fig.2 (b). Scatchard plot analysis of the data shown in (a). The fluorescence 
quenching titration data was fitted with equation shown as inset for 
the binding of midazolam with albumin. 
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Fig.3(a). Quenching of fluorescence of HSA upon midazolam binding.Changes in 
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Fig.3 (b). Percent quench at different HSA concentrations (2,4,6MM). Change 
in percent quench of different HSA concentration at constant 
midazolam ratio for different HSA concentrations. 
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Fig.4. (b) Binding isotherm showing the midazolam induced quenching of HSA 
fluorescence aX B- conformational state with an inset showing the 
scatchard plot for binding parameters. The experimental conditions 
are phosphate buffer pH 9 and at ZS^C. 
number of binding sites with lower affinity in the N-form and less number of 
binding sites with higher affinity in the B-form (three fold increase). 
3.4. Effect of temperature on binding 
A tremendous increase in the binding was observed at low temperature 
for B-conformation while N-conformation showed least binding. The fact that, 
curve showing reduction in fluorescence intensity at fixed thiopental 
concentration vs. variable temperature (Fig.5) was displaced from parallel to a 
higher level at low temperature Indicated that more thiopental was bound at low 
temperature (Fig.5). Furthermore, at higher temperature the deviation of curve 
from parallel behavior showed the confonnational dependent loss of binding. 
Moreover, thennal stability of both confomriations was found to be comparable at 
higher temperature as shown in fig.5. 
3.5. Effect of micro metal ions on binding 
It has also been demonstrated earlier that metal ions bind with protein. 
Moreover, the presence of metal ions directly affects the interaction between the 
drug and the protein (Wilting. 1979; Quagraine. 2001; Zhang. 1999). We studied 
four metal ions Cu^', Fe^', Ni^ *& Zn^' because the traces of these are present in 
blood plasma. Protein concentration of 2.0pM was treated with metal ion and the 
effect was evaluated on the binding reaction by calculating the percent quench in 
its presence. The percent fluorescence was found to be decreased with the 
different treatment of micro metal ions Fig.6a. Among the four metal ions studied, 
the pronounce effect on binding was shown by copper Fig.6b. The highest 
percent quench was observed for copper than iron, nickel and zinc in descending 
order (Table 4). 
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Fig.6 (b). Effect of Cu (II) on HSA fluorescence. HSA fluorescence was 
measured in absence and presence of 10 pM midazolam and 10 pM 
Cu (II). The spectra represents (a) HSA alone (b) HSA +Cu (II) (C) 
HSA + drug (d) HSA + Cu (II) +mldazolam. 
Table .4. EfTect of certain metal ions on midazolam -HSA binding 
Metals 
Control 
Cu 
Fc 
Ni 
Zn 
21 
2t 
2t 
2-t 
Without Drug 
0.0 
15.0 
8.8 
4.0 
3.0 
Percent Quench 
With Drug 
15.0 
33.0 
18.8 
16.4 
12.0 
3.6. Effect of ionic strength 
Studies in the past three decades have concluded that an 
anesthetic binds to hydrophobic regions within the protein through van der waals 
interactions and the hydrophobic effect. (Ekenhoff, 1997; Franks, 1994; 
Hameroffs, 1998). Since it has been shown earlier that electrostatic interactions 
are major binding forces between anesthetic and protein (Franks, 1998). Hence, 
we investigated the effect of ionic environment on binding affinity. Study was 
made on increasing ionic concentration of NaCI (100, 300, and 500 mM) 
Our results indicated that with the increase in the ionic strength, the affinity 
of HSA for thiopental decreased accompanied with the generation of more 
number of binding sites Decrease in binding affinity is inversely proportional to 
NaCI (Na*) concentration. The quenching trend in all three concentrations 
illustrated that at higher concentration of drug the electrostatic forces were more 
dominant than at low molar ratios Fig.7a and the binding occurs more at lower 
ionic concentration. A maximum percent quench was found at 100 mM NaCI 
concentration that is 30%. The binding constant (Kg) exhibited a linear relation 
ship, when log Ka was plotted as a function of-log (Na*) as shown in Fig. 7b. 
3.7. Hydronium (H3O*) ions and binding parameters 
It is well known fact that compartmentalization of human coelomic 
cavity which generates in different compartments with varying hydronium ions 
concentrations and lead to varying charge distribution on protein. Hence to 
assess the effect of hydronium ions we have taken three basic concentrations 10 
^ 10^ and 10"^  for evaluation of capacity and extend of binding. 
We have also investigated binding parameter at different hydronium 
ion concentration. Fig.8a showed the relative fluorescence on titration of 
thiopental 
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Fig.7 (a). Fluorescence quenching trend of HSA at different NaCI concentrations 
at fixed drug /HSA molar ratio, with HSA concentration (2pM). All other 
experimental conditions are same as given in fig.2. 
Fig7 (b). Relationship of binding constant. K of HSA -midazolam at different 
ionic strengths. The log K values obtained for HSA-thiopental 
interaction at varying concentration of NaC1100, 300 and 500mM 
are plotted as the function of -log[Na]. 
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Fig.8(a). Binding isotherms showing the effect of different concentration of H3O' 
ions on midazolam induced quenching of HSA in Tris-HCI buffer at 
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Fig8 (b). Scatchard plot analysis of midazolam HSA binding in the presence of 
different H3O* ions concentration (i) 10'^  (ii) 10'^ (ill) 10"^  M. 
at three (H3O*) concentrations that were 10"^ , 10"^  and 10'^  M. The result 
illustrated the maximum quenching effect in the presence of 10^ M H* ions The 
reduction in the fluorescence was progressive at 10'^  and 10"^  but at 10^ M 
initially the quench was concentration dependant and comparable to 10 ^M H* 
but later it showed saturating trend. The association and binding constants (Kg 
and n respectively) were calculated for all three concentrations of H* ions by 
scatchard plot (Fig.8 b.c&d) and the values obtained were Ka= 0.023 x 10 ,^ 0.015 
X 10® and 0.035 x 10® n = 7.1, 10.7 and 9.7 for 10•^ lO'^and 10"^  M H' ions 
respectively. 
3.8. Conformational changes followed by CO spectroscopy 
The changes in the secondary structure of HSA induced by thiopental 
and its copper complex were also analyzed by circular dischroism spectra. The 
CD spectrum of native HSA alone showed very neat peaks at 208 and 222 nm, 
which are negative. The addition of midazolam alone did not change the spectral 
pattern and the secondary structure (see curve b, Fig 9). However the addition of 
copper with thiopental has drastically changed the ellipticity ( %) as seen in Fig 9 
(curve c), which further increases on addition of the thiopental from (0.2 mM to 
10 mM). The change in ellipticity is accompanied by the decrease in a helix by 
36 % with the 12%decrease in p sheet structure illustrating the destabilization of 
the secondary structure of HSA. 
200 
CD|mdeg] 
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Wavelengthfnml 
Flg.9. The spectra of HSA of native, (a); native+0.2mM midazolam, (b); 
natlve+0.2 mM mldazolam-t-0.2mM Cu (II), (c); native+0.4mM 
mldazolam+0.2mM Cu (II), (d); natlve+0.8mM midazolam+0.2mM Cu (II), 
(e); native+1.0mM midazolam-«-0.2mM Cu (II), (f) respectively. 
4.0 DISCUSSION 
This is the first report that shows a potential binding of midazolam 
with a high affinity and binding capacity for Human serum albumin with various 
parameters. The binding parameters under the influence of modulating factors 
such as substrate dependant binding, conformational state, ionic strength, 
hydronium ion concentration, temperature relation with binding and metal ions 
effect were not been studied earlier. Our study contributes significant information 
from both clinical and pharmacological point of view. 
4.1. Number of binding site and affinity 
We investigate the two types of biding sites for thiopental on HSA. 
Our data, on the decrease in linearity of the quenching pattern of concentration 
dependent binding suggest the presence of two different binding sites on HSA for 
the drug. Moreover, this data also suggest that high affinity binding sites show a 
linear quenching pattern where as low affinity binding sites exhibit unsaturable 
pattern of binding. This finding is consistent with the previous studies carried out 
with other anesthetic (Christensen & Andreasen. 1980). The plot constructed 
from the experiment with constant thiopental concentration and increasing 
albumin concentration shows increase in the magnitude of Ka and n, the binding 
parameters. Such substrate dependent binding has also been reported by Shen 
& Gilbaldi (1974). This could be explained by the fact that each albumin molecule 
represents a large lipophilic or at least hydrophobic area for lipophilic midazolam, 
which provides better site for localization of midazolam molecule and so it makes 
our study in favors of the binding experiment for other lipophilic drugs earned out 
previously showing the similar trend (Christensen. 1980). 
4.2. Modulating factors and binding 
The result of binding in different conformational states shows high 
binding affinity for the B-conformational state of protein as compared to N- state. 
The reason for this discrimination in binding is flexible nature of B-form as 
compare to compact N-form. This is why probably; B-form of protein provides 
better localization of drug and so increases its binding affinity. Another significant 
reason for the strong binding with B-form might be the close proximity of drug 
molecule to the domain III (Dockal. 2000). which is further contributing to 
increase in high affinity binding sites. The increase in binding affinity with the 
decrease in binding capacity suggests the decrease in binding sites of low affinity 
and increase in high affinity binding sites due to conformational change. The 
decrease in binding sites from N- to B- form has also been described previously 
for warfarin (Wilting, 1980). Our results are also consistent with the number of 
reports dealing with conformation dependent binding (Rosen, 1970; Janssen & 
Nelen, 1979). 
We also observed that the variation in the temperature brings a 
significant change in the conformational dependant binding. The curve in figure 6 
shows fluorescence reduction with a constant drug concentration, resulting 
decrease in binding. At low temperature more midazolam is bound. In fact the 
amount of B-form of albumin is reduced from 0.67 to 0.11 (fraction) on reducing 
the temperature (Jcabsen & Faerch, 1980). This is because of the fact that the 
binding forces are reduced with the increase in temperature. But no evidence 
proves that lowering in temperature results in unfolding of the HSA and hence 
provides better accessibility for drug molecules to a new binding site. Our data 
that midazolam binding is increased with the decrease in temperature strongly 
supported by the finding of an increased olive oil/phosphate coefficient at low 
temperature (Christensen, 1983). A significant change in the B-form has been 
observed as compared to N-form, which is again, probably due to conformation 
dependent compact structure of N-form. 
The results about the enhancement of binding interactions in the 
presence of micro metal divalent ions are comparable to the earlier finding on the 
metal ion complexation W\\h albumin (Kragh-Hansen, 1994) suggesting the 
potential of these metal ions present in our body influencing the binding reaction. 
Indeed, the residues at the N- terminus particularly histidine moiety at position 3, 
cys-34 and tryptophan are known to play a critical role in metal binding (Peters, 
1967). Our results suggest maximum binding in the presence of Cu (II) and least 
with Zn (II). This increase in the binding may be due to the formation of metal ion 
bridges, which provides best fit for drug molecule. This phenomenon imply that 
the binding force between the protein and the drug has been enhanced in the 
presence of metal ions, and so affects the pharmacokinetics of the drug in the 
blood plasma. 
4.3. Specificity 
The unsaturable fluorescence quench from binding spectra 
suggests the binding of midazolam molecule at a site possessing number of 
aromatic moieties. Further quenching effect at excitation wavelength for 
tryptophan (295nm) was negligible as compared to quenching at excitation 
wavelength for phenylalanine (280nm); depicts the presence of phenylalanine at 
the drug binding site. Through browsing the different domain structure of HSA, 
we found such a site present in domain III of the protein. As sub-domain IIIB lined 
by aromatic residues (Phe-502. Phe-507, Phe-509, Phe-551) emitting 
fluorescence, which is also advocated further with our conformational dependant 
binding, showing more binding in B-form which results in further opening of 
domain III by breaking the salt bridges (Dockal & Carter, 2000). The 
crystallographic data of subdomain MIA had previously suggested it as one of the 
most important binding site termed site II by 
Sudlow et.al (1976) and can also accommodate diazepam, propofol and other 
aromatic anesthetics. Which further affinn the binding of midazolam at domain III. 
The two class of binding model is also justified by these sites, as the subdomam 
IIIA is shown to be a site with weaker binding affinity as compared to site IIIB 
(Curry, 1999). This elucidates the presence of binding sites for midazolam in 
domain III. 
4.4. Binding forces 
Electrostatic interactions 
Increase in the ionic strength should screen charges in water 
accessible sites and reduce their effect on the ligand binding in the competitive 
way. Thus if electrostatic interactions were important, an increase in the ionic 
strength should reduce their contribution to binding and thus weaken binding due 
to screening effect of ions in these interactions (Liu, 2002). Hence, increase in 
the ionic strength from 100-500 mM weakens the association constant 
suggesting major contribution of electrostatic forces in the binding. The 
quenching trend with different ionic strength shows the effect of ionic strength at 
higher concentration of drug. Which illustrates the interference of ions due to 
their presence in the water accessible binding sites. The maximum quench 
occurs at 500 mM NaCI concentration irrespective of the maximum binding 
affinity at lower ionic strength, this could be explained that with the increasing 
ions concentration binding capacity increases and leading to more binding at 
higher ions concentration. This suggests that with increase in ions there is a 
change in protein conformation, which may lead to unfolding of the structure, and 
the lowering of binding affinity illustrates the generation of low affinity binding 
sites. 
The change in H* ions concentration leads to a difference in charge 
distribution on the protein due to different degree of ionization, depending on 
different pKa value of constituent amino acids. The protein is more ionized at two 
extreme of H* concentrations (10~^ to 10"^ IVI), which in turn generates a strong 
electrostatic force, and hence leads to high binding affinity compare to 10'^M. 
which makes it slow eliminating even at high H i^ons concentration. 
The chloride ion, fluoride ion and n electrons of the midazolam aromatic 
ring contribute negative charges that can interact with cations and other positive 
charges (Dougherty, 1996), which further advocate the electrostatic forces. 
Hydrophobic interactions 
The lipophilic nature of the thiopental predicts the role of 
hydrophobic forces in the interaction. Guided by the Meyer-Overton correlation 
between anesthetic potency and solubility in a lipid like environment, had 
suggested that anesthetics must bind to hydrophobic regions (Franks & Lieb, 
1994). As reported earlier that hydrophobic interactions are responsible for the 
binding of benzodiazepines (Satya, 2002) even these hydrophobic forces are 
employed to separate these benzodiazipines (Mullet, 2001) and further the large 
structure of mizazolam implicates good hydrophobic forces in the interaction. As 
the drug binds to buried hydrophobic sites which are undisturbed by ionic 
strength approachable to water assessable region of the domains, leaving 
hydrophobic interactions as the dominant feature of midazolam-HSA interaction. 
\/an der waals interactions 
In view of the structure of midazolam, which lack formal charges 
and have small dipole moments, van der waals forces must play an important 
role in the stabilizing energetics that govern their binding to a protein (Zhang & 
Yang. 1999). Van der waals forces are derived from short-range, transient 
electrostatic interactions, and can be predicted to be larger for thiopental, since 
its larger surface contact as depicted in the scatchard analysis. Therefore, in 
addition to electrostatic interactions, van der waals forces must also contribute to 
the more capacity and the higher affinity of the midazolam-HSA complex. 
Hydrogen bonds 
Thiopental may act as both a hydrogen bond acceptor and donor, 
due to the presence of both electropositive and electronegative functional groups 
attached to its aromatic ring (Fig 1). In the earlier studies it was found that the 
aromatic ring lies within an apolar pocket with the phenolic hydroxy group in 
close proximity for establishing a hydrogen bond, with main chain moieties of 
Leu"° residue and Ser*" in domain MIA and IIIB respectively (Bhattacharya, 
2000). This is similar as per our elucidation for specificity of binding sites of 
midazolam. 
4.5. Protein secondary structure 
The excessive binding of midazolam to HSA-Cu (II) complex led 
changes in the microenvironment, which in turn destabilize the carrier protein. 
CD data also show no change in ellipticity in the absence of Cu (II) ions, which 
suggests that the copper ions enhanced the binding of midazolam to serum 
albumin. This is probably due to the formation of the metal ion bridges which 
provide the appropriate binding sites for the drug interactions (Peters & Jr. 
Blumenstock, 1967). This observation corroborates the fluorescent data, 
exhibiting significant quenching of protein fluorescence (33%) in the presence of 
midazolam and Cu (II) ions compared to 15 % with midazolam alone. 

Our study concludes a strong interaction between anesthetic 
supplements and human serum albumin, which is the primary mode of transport 
for these drugs. This interaction stabilizes the complex and shows a good 
thermal stability. Moreover, increase in binding parameters at N- conformational 
state illustrates that it is conformational dependent. The metal ions strengthen its 
binding which may lead to increase its span in circulatory system and so its 
effects. The significant binding at higher hydronium ion concentration implicates 
its slow elimination even in the acidic excretory condition. Inspite of the 
hydrophobic forces supposed to be responsible for anesthetic binding, 
electrostatic forces are also contributing in this binding reaction. The changes in 
the secondary structure of HSA upon the interaction of these anesthetics may 
render the binding sites for the vital interactions of other ligands with it. This 
study implicates that this type of reactions may lead to physiological changes in 
the cells of localized area after anesthesia. Furthermore, it may also cause 
severe physio-pathological conditions in the patient. The conformational changes 
strongly favours the paucity of binding sites for the vital interactions in the 
exogenous pathway and henceforth resulting in the accumulation of the toxic 
substances. 
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